Sangamo Therapeutics Inc. (SGMO)

16.25
0.35 2.20
NASDAQ : Health Technology
Prev Close 15.90
Open 15.95
Day Low/High 15.75 / 16.50
52 Wk Low/High 9.70 / 27.50
Volume 2.72M
Avg Volume 2.05M
Exchange NASDAQ
Shares Outstanding 101.67M
Market Cap 1.59B
EPS -0.70
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Sangamo Therapeutics Reports Second Quarter 2018 Financial Results

Sangamo Therapeutics Reports Second Quarter 2018 Financial Results

Company Also Separately Announced Positive Preliminary Data from Phase 1/2 Clinical Trial Evaluating SB-525 Gene Therapy for Hemophilia A

Sangamo To Host Educational Webcast With Hunter Syndrome (MPS II) Expert, Joseph Muenzer, M.D., Ph.D.

Sangamo To Host Educational Webcast With Hunter Syndrome (MPS II) Expert, Joseph Muenzer, M.D., Ph.D.

Dr. Muenzer to review MPS II biology, standard of care, and rationale for the development of SB-913, an investigational genome editing treatment

First Week Of SGMO September 21st Options Trading

First Week Of SGMO September 21st Options Trading

Investors in Sangamo Therapeutics Inc saw new options become available this week, for the September 21st expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the SGMO options chain for the new September 21st contracts and identified one put and one call contract of particular interest.

Sangamo Announces Treatment Of First Patient In Phase 1/2 Clinical Trial Evaluating SB-318 Investigational In Vivo Genome Editing Therapy For MPS I

Sangamo Announces Treatment Of First Patient In Phase 1/2 Clinical Trial Evaluating SB-318 Investigational In Vivo Genome Editing Therapy For MPS I

RICHMOND, Calif., July 23, 2018 /PRNewswire/ -- Sangamo Therapeutics, Inc.

Sangamo Therapeutics To Acquire TxCell

Sangamo Therapeutics To Acquire TxCell

The Proposed Acquisition Would Combine Sangamo's Ex Vivo Gene Editing Capabilities and TxCell's Treg Expertise and Would Position Sangamo as a Leader in CAR-Treg Development

Sangamo Therapeutics Announces Technology Leadership Changes

Sangamo Therapeutics Announces Technology Leadership Changes

RICHMOND, Calif., July 13, 2018 /PRNewswire/ -- Sangamo Therapeutics, Inc.

Sangamo Therapeutics Appoints Karen Smith To Its Board Of Directors

Sangamo Therapeutics Appoints Karen Smith To Its Board Of Directors

RICHMOND, Calif., June 28, 2018 /PRNewswire/ -- Sangamo Therapeutics, Inc.

Traders Are Still Finding Plenty of Stocks That They Want to Buy

Traders Are Still Finding Plenty of Stocks That They Want to Buy

Sentiment is very positive, regardless of what the indices may say.

3 Biotech Best Bets From the 'Stock Picker of the Year'

3 Biotech Best Bets From the 'Stock Picker of the Year'

In 2017, McCamant's model portfolio rose 65%, while his trader's portfolio rose 98%.

Interesting SGMO Put And Call Options For July 20th

Investors in Sangamo Therapeutics Inc saw new options begin trading this week, for the July 20th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the SGMO options chain for the new July 20th contracts and identified one put and one call contract of particular interest.

Bioverativ And Sangamo Announce FDA Acceptance Of IND Application For Gene-Edited Cell Therapy BIVV003 To Treat Sickle Cell Disease

Bioverativ And Sangamo Announce FDA Acceptance Of IND Application For Gene-Edited Cell Therapy BIVV003 To Treat Sickle Cell Disease

Bioverativ Inc., a Sanofi company dedicated to transforming the lives of people with rare blood disorders, and Sangamo Therapeutics, Inc.

Many Names on My Radar

Many Names on My Radar

There is no question that we are becoming extended and ripe for some profit taking.

First Week Of SGMO June 15th Options Trading

Investors in Sangamo Therapeutics Inc saw new options become available this week, for the June 15th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the SGMO options chain for the new June 15th contracts and identified one put and one call contract of particular interest.

The Market Is Finally Rewarding Stock Picking

The Market Is Finally Rewarding Stock Picking

The game plan is to spot the charts that have more room to run.

Markets Recovering From Latest Trump Tweetstorm

Markets Recovering From Latest Trump Tweetstorm

Wall Street discounting talk of bombing Syria from president.

Biotechs Take the Lead This Morning

Biotechs Take the Lead This Morning

Whether this market continues to bounce is going to depend a great degree on the FAANG names.

2 Biotech Stocks to Consider

2 Biotech Stocks to Consider

Many stocks are already at support levels and are offering opportunities to start some positions.

Sangamo Announces Publication In Molecular Therapy Of Preclinical Study Data From MPS II In Vivo Genome Editing Program

Sangamo Announces Publication In Molecular Therapy Of Preclinical Study Data From MPS II In Vivo Genome Editing Program

Study provided proof of concept for development of SB-913 product candidate currently being evaluated in Phase 1/2 clinical trial

TheStreet Quant Rating: D (Sell)